Sirnaomics Ltd.
2257.HK
Hong Kong Stock Exchange5.37
HKD
-0.16
- -
Sirnaomics Ltd.
2257.HK
(Hong Kong Stock Exchange)
Recent
price
5.37
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Sirnaomics Ltd. (2257.HK) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes ribonucleic acid interference (RNAi) therapeutics targeting unmet medical needs in oncology, fibrosis, cardiometabolic diseases, complement-mediated diseases, medical aesthetics and viral infections. The company offers a robust pipeline of over 10 drug candidates delivered via proprietary platforms including Polypeptide Nanoparticle (PNP) and the next-generation GalAhead GalNAc conjugation technology; lead products comprise STP705, a topical siRNA therapy for non-melanoma skin cancers such as squamous cell carcinoma in situ and keloids as well as focal fat reduction in medical aesthetics; STP707, a systemic siRNA therapeutic for solid tumors including liver, kidney, pancreatic, breast, colorectal and melanoma cancers; STP122G, the first GalAhead candidate in Phase I for anticoagulation disorders targeting Factor XI; STP125G for hypertriglyceridemia; STP144G for complement-mediated diseases; STP247G for complement immunologic diseases; STP237G for hypertension combined with familial hypertriglyceridemia; and STP136G for hypertension. Founded in 2007 and headquartered in Wan Chai, Hong Kong, with key subsidiaries in Germantown, Maryland, USA (including Sirnaomics USA and RNAimmune), Suzhou and Guangzhou, China, the company maintains R&D and manufacturing operations across the United States, Greater China and the Asia-Pacific region. Recent developments include a strategic HKD 138 million equity investment from Bloomage Biotech in September 2025 representing approximately 9.44% ownership to accelerate aesthetics and longevity RNAi programs notably STP705 fat reduction alongside new precision-delivery collaborations integrating hyaluronic acid expertise; a prior HKD 58.9 million subscription from Dr. Poon Hung Fai in October 2024 to bolster R&D and operations; expansion of the Guangzhou GMP facility for full-scale production of pipeline injectables including STP707 batches; IND preparations for STP125G and STP144G in 2024; advancement of STP122G into Phase I trials; and establishment of an R&D center at Hong Kong Science Park in 2023 with subsidiaries RNAimmune and EDIRNA.